A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

PHASE3CompletedINTERVENTIONAL
Enrollment

1,250

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Abatacept

Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year

DRUG

Methotrexate

Tablets, Oral, \>= 15 mg, weekly, 1 year

DRUG

Placebo

IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year

Trial Locations (48)

Unknown

Local Institution, Birmingham

Local Institution, Huntsville

Local Institution, Mobile

Local Institution, Phoenix

Local Institution, Scottsdale

Local Institution, Corona

Local Institution, Irvine

Local Institution, La Jolla

Local Institution, Long Beach

Local Institution, Rancho Mirage

Local Institution, Aurora

Local Institution, Colorado Springs

Local Institution, Denver

Local Institution, Hamden

Local Institution, Washington D.C.

Local Institution, Fort Lauderdale

Local Institution, Gainsville

Local Institution, Palm Harbor

Local Institution, Sarasota

Local Institution, St. Petersburg

Local Institution, Chicago

Local Institution, Rockford

Local Institution, Wichita

Local Institution, Coeur d'Alene

Local Institution, Cumberland

Local Institution, Springfield

Local Institution, Duluth

Local Institution, Lincoln

Local Institution, New Brunswick

Local Institution, Albuquerque

Local Institution, Albany

Local Institution, Binghamton

Local Institution, Mineola

Local Institution, New York

Local Institution, Syracuse

Local Institution, The Bronx

Local Institution, Wilmington

Local Institution, Cincinnati

Local Institution, Oklahoma City

Local Institution, Duncansville

Local Institution, Norristown

Local Institution, Sellersville

Local Institution, Willow Grove

Local Institution, North Charleston

Local Institution, Austin

Local Institution, San Antonio

Local Institution, Arlington

Local Institution, Milwaukee

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00048568 - A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate | Biotech Hunter | Biotech Hunter